HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)

DRUG3 trials

Sponsors

Global Alliance for TB Drug Development, Thirty Respiratory Limited, TASK Applied Science

Conditions

Pulmonary TuberculosesTuberculosis, PulmonaryTuberculosis, Pulmonary, Drug SensitiveTuberculosis, Pulmonary, Multi Drug-resistant

Phase 2

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

RecruitingNCT07073638

Thirty Respiratory LimitedPulmonary Tuberculoses

Start: 2025-10-13End: 2026-11-15Target: 24Updated: 2026-01-12

Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

Not yet recruitingNCT07773610

TASK Applied ScienceTuberculosis, Pulmonary

Start: 2026-07-23End: 2027-12-30Target: 135Updated: 2026-08-19

Phase 3

Shortening Treatment by Advancing Novel Drugs

CompletedNCT02342886

Global Alliance for TB Drug DevelopmentTuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant

Start: 2015-02-28End: 2018-05-31Updated: 2019-03-26

Related Papers

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

BMC Infectious Diseases2016-08-2732 citations